Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: The need for integration for optimal efficacy?

Julia K. Tietze, Gail D. Sckisel, Hui Hua Hsiao, William J Murphy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Due to its immunogenecity and evidence of immune responses resulting in tumor regression, metastatic melanoma has been the target for numerous immunotherapeutic approaches. Unfortunately, based on the clinical outcomes, even the successful induction of tumor-specific responses does not correlate with efficacy. Immunotherapies can be divided into antigen-specific approaches, which seek to induce T cells specific to one or several known tumor associated antigens (TAA), or with antigen-nonspecific approaches, which generally activate T cells to become nonspecifically lytic effectors. Here the authors critically review the different immunotherapeutic approaches in melanoma.

Original languageEnglish (US)
Pages (from-to)238-293
Number of pages56
JournalInternational Reviews of Immunology
Volume30
Issue number5-6
DOIs
StatePublished - Oct 2011

Fingerprint

Melanoma
T-Lymphocytes
Antigens
Neoplasm Antigens
Immunotherapy
Neoplasms

Keywords

  • Adoptive transfer
  • Antibody
  • Antigen specific and nonspecific
  • Cytokine
  • Immunotherapy
  • Melanoma
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma : The need for integration for optimal efficacy? / Tietze, Julia K.; Sckisel, Gail D.; Hsiao, Hui Hua; Murphy, William J.

In: International Reviews of Immunology, Vol. 30, No. 5-6, 10.2011, p. 238-293.

Research output: Contribution to journalArticle

@article{02a629c5aa2d489ebc336b2b842d96a0,
title = "Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: The need for integration for optimal efficacy?",
abstract = "Due to its immunogenecity and evidence of immune responses resulting in tumor regression, metastatic melanoma has been the target for numerous immunotherapeutic approaches. Unfortunately, based on the clinical outcomes, even the successful induction of tumor-specific responses does not correlate with efficacy. Immunotherapies can be divided into antigen-specific approaches, which seek to induce T cells specific to one or several known tumor associated antigens (TAA), or with antigen-nonspecific approaches, which generally activate T cells to become nonspecifically lytic effectors. Here the authors critically review the different immunotherapeutic approaches in melanoma.",
keywords = "Adoptive transfer, Antibody, Antigen specific and nonspecific, Cytokine, Immunotherapy, Melanoma, Vaccine",
author = "Tietze, {Julia K.} and Sckisel, {Gail D.} and Hsiao, {Hui Hua} and Murphy, {William J}",
year = "2011",
month = "10",
doi = "10.3109/08830185.2011.598977",
language = "English (US)",
volume = "30",
pages = "238--293",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma

T2 - The need for integration for optimal efficacy?

AU - Tietze, Julia K.

AU - Sckisel, Gail D.

AU - Hsiao, Hui Hua

AU - Murphy, William J

PY - 2011/10

Y1 - 2011/10

N2 - Due to its immunogenecity and evidence of immune responses resulting in tumor regression, metastatic melanoma has been the target for numerous immunotherapeutic approaches. Unfortunately, based on the clinical outcomes, even the successful induction of tumor-specific responses does not correlate with efficacy. Immunotherapies can be divided into antigen-specific approaches, which seek to induce T cells specific to one or several known tumor associated antigens (TAA), or with antigen-nonspecific approaches, which generally activate T cells to become nonspecifically lytic effectors. Here the authors critically review the different immunotherapeutic approaches in melanoma.

AB - Due to its immunogenecity and evidence of immune responses resulting in tumor regression, metastatic melanoma has been the target for numerous immunotherapeutic approaches. Unfortunately, based on the clinical outcomes, even the successful induction of tumor-specific responses does not correlate with efficacy. Immunotherapies can be divided into antigen-specific approaches, which seek to induce T cells specific to one or several known tumor associated antigens (TAA), or with antigen-nonspecific approaches, which generally activate T cells to become nonspecifically lytic effectors. Here the authors critically review the different immunotherapeutic approaches in melanoma.

KW - Adoptive transfer

KW - Antibody

KW - Antigen specific and nonspecific

KW - Cytokine

KW - Immunotherapy

KW - Melanoma

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=80855139961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855139961&partnerID=8YFLogxK

U2 - 10.3109/08830185.2011.598977

DO - 10.3109/08830185.2011.598977

M3 - Article

C2 - 22053969

AN - SCOPUS:80855139961

VL - 30

SP - 238

EP - 293

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 5-6

ER -